Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Phone+1-206-8012100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions
What is Cascadian Therapeutics' stock symbol?
Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC."
How were Cascadian Therapeutics' earnings last quarter?
Cascadian Therapeutics Inc (NASDAQ:CASC) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the business posted ($0.09) earnings per share. View Cascadian Therapeutics' Earnings History.
Has Cascadian Therapeutics been receiving favorable news coverage?
Headlines about CASC stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cascadian Therapeutics earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
What other stocks do shareholders of Cascadian Therapeutics own?
Who are Cascadian Therapeutics' key executives?
Cascadian Therapeutics' management team includes the folowing people:
- Christopher S. Henney Ph.D., Chairman of the Board (Age 76)
- Scott D. Myers, President, Chief Executive Officer, Director (Age 51)
- Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary (Age 51)
- Gary W. Christianson, Chief Operating Officer (Age 61)
- Scott Peterson Ph.D., Chief Scientific Officer (Age 54)
- Robert W. Azelby, Director (Age 49)
- Gwendolyn A. Fyfe M.D., Independent Director (Age 65)
- Steven P. James, Independent Director (Age 58)
- Ted W. Love M.D., Independent Director (Age 58)
- Daniel Keith Spiegelman, Independent Director (Age 58)
What is Cascadian Therapeutics' official website?
How can I contact Cascadian Therapeutics?
Cascadian Therapeutics' mailing address is 3101 Western Ave Ste 600, SEATTLE, WA 98121-3047, United States. The biopharmaceutical company can be reached via phone at +1-206-8012100 or via email at [email protected]
MarketBeat Community Rating for Cascadian Therapeutics (NASDAQ CASC)
MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe CASC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASC will underperform the S&P 500 over the long term. You may vote once every thirty days.
